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The System xc- antiporter is plasma membrane transporter that mediates the exchange of 
extracellular L-cystine with intracellular L-glutamate.  This exchange is significant 
within the context of the CNS because the import of L-cystine is required for the 
synthesis of the antioxidant glutathione, while the efflux of L-glutamate has the potential 
to contribute to either excitatory signaling or excitotoxic pathology.  Changes in the 
activity of the transport system have been suggested to contribute to the underlying 
pathological mechanisms of a variety of CNS disorders, one of the most prominent of 
which is it highly enriched expression glial brain tumors.  In an effort to produce more 
potent System xc- blocker, we have been using amino-3-carboxy-5-methylisoxazole 
propionic acid (ACPA) as a scaffold for inhibitor development.  We previously 
demonstrated that the addition of lipophilic aryl groups to either the #4 or #5 position on 
the isoxazole ring markedly increased the inhibitory activity at System xc-.  In the present 
work a novel series of analogues has been prepared in which aryl groups have been 
introduced at both the #4 and #5 positions.  In contrast to the competitive action of the 
mono-substituted analogues, kinetic analyses indicate that the di-substituted isoxazoles 
block System XC--mediated uptake of 3H-L-glutamate into SNB-19 activity by a 
noncompetitive mechanism.  These new analogues appear to be the first noncompetitive 
inhibitors identified for this transport system, as well as being among the most potent 
blockers identified to date.  These diaryl-isoxazoles should be of value in assessing the 
physiological roles and molecular structure of System xc-.
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Chapter 1.  Introduction 
1.1 Background on System xc- 
System xc- (Sxc-) is an amino acid transporter that, under physiological conditions, 
mediates the exchange of extracellular L-cystine (L-Cys2) for intracellular L-glutamate 
(L-Glu) across the plasma membrane (Bridges et al., 2012b).  
As an antiporter, Sxc- performs a 1:1 exchange of intracellular and extracellular amino 
acids.  The direction of this exchange is mediated by the concentration gradients of 
substrates across the cell membrane. Early studies with Sxc- showed that the antiporter 
acts in a sodium-independent, chloride-dependent, electroneutral manner; it transports L-
Cys2 and L-Glu in an anionic form; and that both L-Cys2 and L-Glu are capable of 
inhibiting the transport of one another.  Under normal physiologic conditions the 
intracellular concentration of L-Glu well exceeds that of L-Cys2 due in part to the uptake 
of glutamate through excitatory amino acid transporters (EAAT), as well as the rapid 
reduction of L-Cys2 to L-cysteine (L-CysH) (Bridges et al., 2012b). 
Sxc- has been found to play a role in a variety of cells throughout different organ systems.  
It has been characterized in cells such as fibroblasts, macrophages, hepatocytes, 
endothelial cells, and the brush border membranes of renal tubules and the intestine 
(Bannai, 1986; Burdo et al., 2006; Hosoya et al., 2002; Sasaki et al., 2002; Sato et al., 
1999).   However, the majority of the focus has been on the localization of Sxc- within the 
CNS, including neurons, glial cells, and within the blood-brain barrier (Burdo et al., 
2006).   
Both sides of the Sxc- exchange reaction are potentially important in the function of the 
CNS, as the import L-Cys2 is needed for the synthesis of glutathione and oxidative 
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protection (Halliwell, 2006), while the exported L-Glu could contribute to neuronal 
communication, as well as neuronal dysfunction (Bridges et al., 2012a).  Once inside the 
cell, L-Cys2 is rapidly reduced to L-CysH, which then serves as the rate-limiting 
precursor for glutathione production (Sagara et al., 1993).  The efflux of L-CysH and 
glutathione (through extracellular metabolism by γ-gluamyl-transpeptidase and 
aminopeptidase N to form L-CysH) are then available to provide antioxidant precursors 
to surrounding cells, such as mature neurons, which have little to no Sxc- activity and are 
therefore dependent on the uptake of L-CysH (Dringen et al., 1999; Sagara et al., 1993).  
Beyond its antioxidant properties, glutathione has also been implicated in a variety of 
regulatory pathways including modulating the activity of proteins possessing a critical 
cysteine-residue; and interacting with receptors to influence signal transduction (Filomeni 
et al., 2002; Janaky et al., 1999; Seib et al., 2011).   
Conversely, excess Sxc- activity can result in elevated synaptic and extrasynaptic 
concentrations of L-Glu leading to excitotoxicity and cell death, which is seen in glial 
brain tumors (Ye et al., 1999) and inflammation induced by microglia (Shih et al., 2006).  
An example of how both of these processes interconnect is in brain tumor cells where 
increased glutathione synthesis can result in chemoresistance and increased clearance of 
xenobiotics (Huang et al., 2005), while increased efflux of L-Glu leads to excitotoxicity 
and cell death (Ye et al., 1999).   
The dual nature of Sxc- to maintain glutathione levels and L-Glu homeostasis is both 
advantageous and deleterious. The protective effects of glutathione are exerted through 
glutathione-mediated elimination pathways, as well as reduction of oxidative damage to 
proteins and lipids.  The increased antioxidant properties provided by the production of 
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glutathione provide protection from many potentially toxic insults, including L-Glu itself.  
The complex balance of these two processes has been implicated in a variety of CNS 
diseases.  A loss of Sxc- function has been implicated in the etiology of chronic cocaine 
and nicotine addiction and relapse, as well as psychiatric disorders such as schizophrenia 
(Baker et al., 2003; Bridges et al., 2012a; Knackstedt et al., 2008; Madayag et al., 2010).  
 
1.2  Structure and Family Class 
Sxc- is a member of the heteromeric amino acid transporter (HAT) family (Broer et al., 
2002; Palacin et al., 2005).  These transporters are heterodimers composed of an N-
glycosylated “heavy chain” (4F2hc, Solute Carrier SLC3 family) covalently linked via a 
disulphide bond to a non-glycosylated “light chain” (xCT, SLC7A11).  For this reason, 
HATs are also referred to as glycoprotein-associated amino acid transporters.  The 4F2hc 
heavy subunit consists of an intracellular N terminus, a single transmembrane domain, 
and a large extracellular C terminus.  The 4F2hc subunit is thought to be responsible for 
the trafficking of the light chain (the light subunit cannot reach the cell membrane 
without interacting with the heavy subunit) and for cell surface expression.   The xCT 
subunit of Sxc- is thought to be responsible for the transport activity (Broer et al., 2002; 
Palacin et al., 2005).  Structural models of Sxc- indicate that xCT has 12 transmembrane 
domains (TMDs), with N and C termini located inside the cell, and a re-entrant loop 
between TMD 2 and 3 that appears to participate in substrate binding and 
translocation(Gasol et al., 2004) (See Figure 1.1). 
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Figure 1.1. A Heteromeric Amino Acid Structure 
 
 
 
Showing the heavy-chain subunit (4F2hc) in pink, and the light-chain subunit (xCT) in 
blue. Palacin et al., 2005, Physiol. 20:112. 
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1.3  Pharmacology 
Early studies with Sxc- focused on identifying inhibitors to provide insight into the 
structure activity relationships (SARs) that determine Sxc- selectivity, and to aid in the 
development of pharmacophore models.  
 
1.3.1  Substrates/Early Inhibitors: 
Initial pharmacological studies on Sxc- established L-Cys2 and L-Glu as substrates of the 
transporter, as well as competitive inhibitors of each other.  Structural mimics of these 
endogenous substrates were then used to further define key features of the transporters 
specificity.  For example, Sxc- exhibits a stereo-selective preference for L-amino acids.  
Furthermore, use of acyclic EAA analogues with shorter, “aspartate like” chain lengths 
demonstrated an inability to bind at Sxc-, thus distinguishing it from the EAAT transport 
systems (Patel et al., 2004).  Other defining characteristics include: the ability of L-α-
aminoadipate and L-α-aminopimelate to act as inhibitors (demonstrating that longer 
chain lengths can be tolerated); the inactivity of L-homocystine as an inhibitor 
(demonstrating the transporters limit to accommodate increasing chain lengths); and that 
SO3- and SO2- groups can replace a distal COO- (inhibition with L-homocysteate, L-
serine-O-sulphate, and L-homocysteine sulphinate), but PO32- groups cannot (lack of 
inhibition with L-serine-O-phosphate) (Bridges et al., 2012b).   
 
1.3.2  Conformationally Constrained Inhibitors 
In an attempt to identify more potent inhibitors for Sxc-, several comformationally 
constrained analogues of Glu where characterized (Patel et al., 2004).  This strategy 
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restricts bond rotation so the functional groups on the molecule can be locked in a 
configuration that hypothetically mimics that of the endogenous substrate when it binds 
the transporter.  Past studies have identified four such analogues that inhibit Sxc-, 
including quisqualate (QA), 4-S-carboxy-phenylglycine (4-S-CPG), ibotenate (IBO), and 
(RS)-4-Br-homoibotenate. Of note, each of these compounds is also known for exhibiting 
activity at other iGluRs and mGluRs.  Studies examining substrate activity of these 
analogues showed IBO to have comparable substrate activity to that of L-Cys2 (Patel et 
al., 2004).  While (RS)-4-Br-homoibotenate and QA also acted as substrates, their ability 
to be transported was considerably less than that of IBO.   The two most potent inhibitors, 
QA and 4-S-CPG (% of control 1±1 and 3±1, respectively) were the least active as 
substrates.  Therefore demonstrating that the inhibitors with the highest affinities may 
promote binding, but preclude the translocation of the amino acid (Patel et al., 2004) 
(refer to Figure 2.1 in chapter 2).   
The action of QA as a potent inhibitor at Sxc- inspired the idea for the use of isoxazoles as 
scaffolds for the development of additional inhibitors of the transporter (Patel et al., 
2010).  Although QA blocked Sxc-, other closely related iGluR agonists, such as 
aminomethyl isoxazole propionic acid (AMPA) did not.  Further work based on the 
structure of AMPA led to the development of a series of amino-3-carboxy-5-
methylisoxazole propionic acid (ACPA) analogues and non-amino acid biosteres of 
ACPA, e.g. hydrazone acids (Matti et al., 2013; Patel et al., 2010).  It was found that the 
addition of lipophilic groups to the ACPA template produced inhibitors with affinities 
comparable to that of L-Cys2.  The Sxc- structure activity relationship (SAR) studies 
allowed the distinguishing characteristics between GluR2 and Sxc- binding sites to be 
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delineated, as well as demonstrated the presence of lipophilic binding domains adjacent 
to the substrate-binding site within the transporter (see Figure 1.2).  To further assess the 
relative position of these lipophilic domains, several 4,5-di-substituted ACPA derivatives 
were prepared to test whether the aryl groups were interacting with one or two distinct 
sites (Patel et al., 2010).  Although less potent than the mono-substituted isoxazoles, the 
use of the “hybrid” isoxazoles, which contained lipophilic substituents at both positions 4 
and 5, confirmed the presence of two distinct lipophilic domains within the binding 
pocket. When tested for substrate activity, it was found that these 4,5-di-substituted 
inhibitors could not act as substrates of Sxc-, suggesting that even though the binding site 
could accommodate the added steric bulk, the additional lipophilic groups precluded 
translocation.  In addition, extensive kinetic analysis demonstrated that the ACPA 
analogue, S-2-napthyl-ethyl-ACPA acted via competitive inhibition (Patel et al., 2010).   
Along with 4-S-CPG, one of the most potent inhibitors of Sxc- characterized to date is 
sulfasalazine (SSZ; 6-oxo-3-(2-[4(N-pyridin-2ylsulphamoyl)phenyl]diazenyl-cyclohexa-
1,4-dienecarboxylic acid)) (Gout et al., 2001).  SSZ is more commonly used for its anti-
inflammatory properties in diseases such as Chron’s and Rheumatoid Arthritis.  As a 
prodrug, SSZ is broken down into sulphapyridine and 5-amino salicylic acid to exert its 
anti-inflammatory effect, but only the prodrug form of SSZ is capable of inhibiting 
activity at Sxc-.  Although SSZ, like many Sxc- inhibitors, contains a benzoic acid moiety, 
it lacks the prototypical L-α-amino acid head group.  However, SSZ maintains potency 
equal to that of 4-S-CPG, suggesting that portions of SSZ may interact effectively enough 
with other domains of the Sxc- binding site so that the interactions with an L-α-amino 
acid head group are no longer required (Bridges et al., 2012b).   
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Figure 1.2. A Ligand-Based Pharmacophore model of Sxc-         
 
 
 
A ligand-based superposition, 3D pharmacophore model for the substrate binding on Sxc-.  
A & B, L-Glu in green; L-Cys2 in yellow; QA in teal; 4-S-CPG in purple; NACPA in red; 
and TFMIH in orange.  F, pharmacophore binding template.   
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1.4  Kinetics of Transporter Inhibition 
 
1.4.1  Competitive inhibition 
One of the most common mechanisms of inhibition of transporters and enzymes is 
competitive inhibition.  In this mechanism, binding of the substrate and inhibitor are 
mutually exclusive and only one can bind at a time.  This most often occurs when the 
inhibitor is binding to the same site as the substrate.  In enzyme kinetics, a competitive 
inhibitor acts by decreasing the number of free enzyme molecules available to bind 
substrate, and eventually form product.  This process is diagramed in Figure 1.3.  
With competitive inhibition, the substrate and inhibitor exert reciprocal effects on the 
concentration of EI and ES complexes.   Therefore, increasing the concentration of 
substrate decreases the concentration of EI complex and raises the reaction velocity.   In 
other words, by increasing the amount of substrate the inhibitor can be out-competed for 
the binding site and the transporter can eventually attain its maximum velocity (or Vmax).  
The amount of substrate needed to completely overcome inhibition depends on the 
concentration of inhibitor present, its affinity for the enzyme (Ki), and the Km for the 
substrate. 
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Figure 1.3: Enzyme Kinetics for Competitive Inhibition 
 
 
 
Scheme diagramming the enzyme kinetics for competitive inhibition. E, enzyme; I, 
inhibitor; k, rate constant; Ki, inhibitory constant; S, substrate; P, product.   
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For Sxc-, competitive inhibition is best exemplified with the endogenous substrate L-
cystine.   Figure 3.1 in the supplemental data shows a graphical presentation of 
competitive inhibition with L-cystine using three separate kinetic analyses: a Michaelis-
Menten plot, a Lineweaver-Burk plot, and an Eadie-Hofstee plot.  Since increasing 
substrate concentration can overcome inhibition with a competitive inhibitor, the 
maximum transport velocity (Vmax) remains constant.  However, the apparent value of the 
Michaelis-Menten constant (Km) increases.  This is best seen in the Lineweaver-Burk and 
Eadie-Hofstee plots, where the lines intersecting at the Y-axis represent constant Vmax 
values in both graphs.  The Ki value for competitive inhibitors can be determined using 
replots of the slopes from the Lineweaver-Burk graphs vs. [I].  These replots can also be 
used to distinguish between competitive and noncompetitive inhibition.  The replot of 
Km.apparent vs. [I] is linear for competitive mechanisms, while the replot of Vmax.apparent  vs. 
[I] is linear for noncompetitive mechanisms (Newell et al., 2013; Segel, 1993).     
 
1.4.2  Noncompetitive inhibition 
Noncompetitive inhibition occurs when the substrate and inhibitor bind reversibly and 
independently at different sites, meaning that the substrate can bind both E and EI, and 
the inhibitor can bind both E and ES complexes.  This process is diagramed in Figure 
1.4. 
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Figure 1.4: Enzyme Kinetics for Noncompetitive Inhibition 
 
Sheme diagraming the enzyme kinetics for a noncompetitive inhibitor. E, enzyme; I, 
inhibitor; k, rate constant; Ki, inhibitory constant; S, substrate; P, product.   
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While the enzyme-inhibitor complex (or in the case of Sxc- the transporter-inhibitor 
complex) can still bind the substrate, its efficiency at transforming/transporting that 
substrate is decreased; reflected by a decrease in Vmax.  However, the apparent Km 
value remains constant for noncompetitive inhibitors. In other words, in noncompetitive 
inhibition increasing the amount of substrate will not overcome the binding of the 
inhibitor.  Therefore, the transporter will never reach its maximum velocity (Vmax) as 
long as there is inhibitor present.  For “pure” noncompetitive inhibitors, the E and EI 
have equal affinity for the substrate, and the EIS complex does not generate product.  In 
more complex types of noncompetitive inhibition, the binding of the inhibitor does affect 
the apparent affinity of the enzyme for the substrate, causing the lines of the double-
reciprocal plot (Lineweaver-Burk plot) to intersect in the third or fourth quadrant 
(meaning the transporter has less affinity for the substrate, represented by a higher 
Kmapparent value) (Segel, 1993). 
These more complex mechanisms of noncompetitive inhibition can also be evaluated by 
using replots from the Lineweaver-Burk graphs of slope vs. [I] and 1/Vmax.apparent vs. [I].  
If both the slope and the 1/Vmax.apparent replots yield similar Ki values, the analogue is 
considered to be acting as a “pure” noncompetitive inhibitor (where the binding of the 
inhibitor does not alter the binding of the substrate); see Figure 3.8 of supplemental data.  
However, if the Ki value from the 1/Vmax.apparent vs. [I] is considerably higher than that of 
the Ki value from the slope vs. [I], this would suggest that the binding of the inhibitor 
decreases the affinity with which the transporter binds the substrate; see Figure 3.4 of 
supplemental data (Segel, 1993).   
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1.5   Present Work with Sxc- 
Previous studies carried out by our lab have demonstrated that isoxazoles with lipophilic 
modifications at either the #4 or #5 position of the heterocyclic ACPA base structure 
exhibit increased inhibitory activity at Sxc-. In the present work, a novel set of isoxazole 
compounds containing lipophilic aryl groups at both the #4 and #5 positions were 
developed and assessed for inhibitory activity at Sxc-. The development of di-substituted 
analogues was used to confirm the presence of multiple lipophilic binding pockets within 
the binding site.  These 4,5-di-subsituted analogues also underwent extensive kinetic 
analysis to characterize their mechanism of inhibition.  As will be seen in the following 
chapter, our structure activity studies have led to the identification of both competitive 
and noncompetitive inhibitors.  A select sample of these inhibitors will be presented in 
Chapter 2, and an expanded library of compounds is presented in Chapter 3.  
Demonstration of noncompetitive inhibition is a very interesting discovery since no 
noncompetitive inhibitors have been developed for this target.  This finding could mean 
the discovery of a new allosteric binding site within the transporter, which could lead to 
development of a new class of compounds with increased potency and specificity at Sxc-.   
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Chapter 2. Neurochemistry International Publication 
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ABSTRACT 
The System XC- antiporter is plasma membrane transporter that mediates the exchange of 
extracellular L-cystine with intracellular L-glutamate.  This exchange is significant 
within the context of the CNS because the import of L-cystine is required for the 
synthesis of the antioxidant glutathione, while the efflux of L-glutamate has the potential 
to contribute to either excitatory signaling or excitotoxic pathology.  Changes in the 
activity of the transport system have been suggested to contribute to the underlying 
pathological mechanisms of a variety of CNS disorders, one of the most prominent of 
which is it highly enriched expression glial brain tumors.  In an effort to produce more 
potent System XC- blocker, we have been using amino-3-carboxy-5-methylisoxazole 
propionic acid (ACPA) as a scaffold for inhibitor development.  We previously 
demonstrated that the addition of lipophilic aryl groups to either the #4 or #5 position on 
the isoxazole ring markedly increased the inhibitory activity at System XC-.  In the 
present work a novel series of analogues has been prepared in which aryl groups have 
been introduced at both the #4 and #5 positions.  In contrast to the competitive action of 
the mono-substituted analogues, kinetic analyses indicate that the di-substituted 
isoxazoles block System XC--mediated uptake of 3H-L-glutamate into SNB-19 activity by 
a noncompetitive mechanism.  These new analogues appear to be the first noncompetitive 
inhibitors identified for this transport system, as well as being among the most potent 
blockers identified to date.  These diaryl-isoxazoles should be of value in assessing the 
physiological roles and molecular structure of System XC-. 
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1. INTRODUCTION 
The System XC- (SXc-) antiporter is a plasma membrane transporter present in multiple 
cell types that typically mediates the exchange of extracellular L-cystine (L-Cys2) with 
intracellular L-glutamate (L-Glu) (for review see: (Bridges et al., 2012a; Bridges et al., 
2012b; Lewerenz et al., 2013).  Functioning as an obligate exchanger, the antiporter 
utilizes the L-Glu concentration gradient generated by the Na-dependent excitatory amino 
acid transporters (EAATs) to drive the uptake of L-Cys2.  Once inside the cell, the L-Cys2 
is rapidly reduced to L-cysteine (L-CysH) where, among many metabolic roles, it serves 
as a rate-limiting precursor in the synthesis of the glutathione.  While studies in most 
cells have focused on the role of SXc- in glutathione production and antioxidant 
protection, the requisite efflux of L-Glu through the antiporter carries with it added 
significance in the CNS, where this L-Glu has the potential to contribute to both 
excitatory signaling and excitotoxic pathology.  When both the import of L-Cys2 and the 
export of L-Glu are taken into account, the SXc- antiporter has been linked to a very wide 
array of physiological and pathological processes including: brain tumor growth (Watkins 
et al., 2012), drug addiction (Madayag et al., 2010; Reissner et al., 2010), 
chemosensitivity and chemoresistance (Huang et al., 2005), viral pathology (Espey et al., 
1998), oxidative protection (Shih et al., 2006), the operation of the blood brain barrier 
(Hosoya et al., 2002), neurotransmitter release (Baker et al., 2002), and synaptic 
organization (Augustin et al., 2007).  Of particular interest, is the role of SXc- in gliomas, 
where astrocytoma cells express markedly enriched levels of SXc- and the obligate export 
of L-Glu that accompanies the import of Cys2 (possibly to meet the increased synthetic 
demands for GSH) appears large enough to produce an excitotoxic necrosis that may aid 
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tumor growth, migration and the production of peritumoral seizures (Lyons et al., 2007; 
Patel et al., 2004; Sontheimer, 2008; Ye et al., 1999).  Significantly, the development of 
more potent and selective blockers of SXc- hold considerable potential to suppress the 
growth of primary brain tumors(Sontheimer et al., 2012).   
Sxc- is a eukaryotic Heteromeric Amino acid Transporter (HAT) (aka glycoprotein-
associated amino acid exchangers) classified within the Amino acid, Polyamine, and 
organic Cation (APC) transporter super-family and L-Amino acid Transporter (LAT) 
family (Palacin et al., 2005; Verrey et al., 2004).  As the HAT classification suggests, 
SxC- is composed of a glycoslated "heavy chain" required for the trafficking and cell 
surface expression of the dimer (4F2hc aka CD98, SLC3 family) and a "light chain" that 
mediates transport activity (xCT, SLC7A11).  Structural studies on the xCT subunit 
indicate that it possesses 12 transmembrane domains (TMDs), intracellular N and C 
termini, and a reentrant loop between TMD 2 and 3 that may participate in substrate 
binding and translocation (Gasol et al., 2004; Jimenez-Vidal et al., 2004). While 
physiologically SxC- mediates the exchange of intracellular L-Glu and extracellular L-
Cys2, its activity can be followed by quantifying the uptake of either radiolabeled 
substrate, with each acting as a competitive inhibitor of the other.  When compared to the 
EAATs, SxC- exhibits a distinct ionic dependency (Cl-dependent, Na-independent) and 
pharmacological specificity (Bridges et al., 2012b).  Unfortunately, many of compounds 
initially identified as inhibitors of SxC- are also well known for interacting with other 
components of the EAA system (e.g., quisqualate, ibotenate, serine-O-sulfate and bromo-
homo-ibotenate), decreasing their utility for functional studies in more complex 
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physiological preparations.  For these reasons we have been pursuing the development of 
more potent and selective inhibitors of SxC-. 
Not withstanding the issue of cross-reactivity, the actions of the isoxazoles and closely 
related heterocyclics mentioned above prompted the development of a series of 
derivatives based upon amino-3-carboxy-5-methylisoxazole propionic acid (ACPA).  
While ACPA exhibits little or no activity itself, the systematic addition of lipophilic 
substituents onto its isoxazole ring has yielded a growing library on increasingly potent 
SxC- inhibitors (Matti et al., 2013; Patel et al., 2010).  The more effective inhibitors 
within this series included the introduction of benzyl or naphthyl-based aryl groups at 
two positions on the isoxazole ring: i) replacing the methyl moiety at position #4 or, ii) 
via a hydrazone linkage, replacing the ethyl amino acid group at position #5.  In all cases 
kinetically examined in detail, the analogues acted as competitive blockers of the SxC--
mediated uptake of 3H-L-Glu, leading to the conclusion that there were lipophilic 
domains adjacent to the substrate binding site on the transport protein.  To further assess 
the relative position of these lipophilic domains, several 4,5-di-substituted ACPA 
derivatives were prepared to test whether the aryl groups were interacting with one or two 
distinct sites (Patel et al., 2010).  While considerably less active as SxC- inhibitors than a 
number of the mono-substituted isoxazoles, the results nonetheless were consistent with 
the presence of two lipophilic "pockets" on the antiporter.  In the present work we have 
continued optimizing aryl group substituents at the 4 and 5 positions of the isoxazole ring 
of the ACPA template to generate some of the most potent inhibitors of SxC- yet 
identified.  Further, kinetic analyses indicate that unlike the parent mono-substituted 
derivatives, these "hybrid" di-substituted isoxazoles act as noncompetitive inhibitors of 
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SxC-.  These findings identify a new pharmacological strategy with which to regulate SxC- 
activity, as well as raise interesting questions as to the position of the lipophilic domains 
relative to the substrate binding site on the transporter. 
 
2. METHODS AND MATERIALS 
2.1 Chemistry: Synthesis 
The novel analogues reported in this study were prepared from the bromo acetal 6 shown 
in Scheme 2.1 (Nelson et al., 2008). Suzuki-Miyaura palladium (McDaniel et al., 2011) 
catalyzed coupling with the corresponding arylboronic acids put the C-5 aryl in place, 7-
9, hydrolysis of the acetal, hydrazone condensation (Patel et al., 2010), and hydroylsis of 
the C-3 ester under basic conditions (Matti et al., 2013) to arrive at the products 2-4 was 
then accomplished as previously described. 
2.2 Cell Culture 
SNB-19 glioma cells, purchased from American Type Culture Collection (Manassas, 
VA), were grown in DMEM/F-12 medium (pH 7.4) containing 1 mM pyruvate and 16 
mM NaHCO3 and supplemented with 10% fetal calf serum. The cells were cultured in 
150 cm2 flasks (Corning) and maintained at 37 °C in a humidified atmosphere of 5% 
CO2. In the [3H]-L-glutamate uptake experiments, cells were seeded in 12 well culture 
plates (Costar) at a density of 5 x 104 cells/well and maintained for 3 days until 80-90% 
confluent.  Protein concentrations were determined by the bicinchoninic acid (BCA) 
method (Pierce).   
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Figure 2.1: Structures of Isoxasole-Based Ligands 
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Scheme 2.1: Reagents and Reaction Conditions 
 
 
 
Reagents and reaction conditions: a. NBS CCl4 b. ArB(OH)2, PdL4, CsCO3 c TsOH, 
Acetone d. Bis-3,5-trifluoromethylphenylhydrazine e. 3N NaOH f. HCl 
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2.3 Glutamate Uptake Assay 
Uptake of 3H-L-glutamate into cultured cells was quantified using a modification of the 
procedure of Martin and Shane as previously described Patel et al., 2010. Briefly, 
individual wells after removal of culture media, were rinsed three times and pre-
incubated in 1 ml Na+-free HEPES buffered (pH 7.4) Hank’s balanced salt solution 
(HBHS) at 30 °C for 5 min. The Na+-free buffer contained: 137.5 mM choline Cl, 5.36 
mM KCl, 0.77 mM KH2PO4, 0.71 mM MgSO4.7H2O, 1.1 mM CaCl2, 10 mM D-glucose, 
and 10 mM HEPES. Uptake was initiated by aspiration of the pre-incubation buffer and 
the addition of a 500 ml aliquot of Na+-free transport buffer containing 3H-L-glutamate 
(4–16 mCi/ml) mixed with L-glutamate (10–500 mM, final concentration). In those 
assays that evaluated inhibitor activity, the 500 ml aliquot of transport buffer contained 
both the 3H-L-glutamate and potential inhibitors to ensure simultaneous addition. 
Following a 5 min incubation at 30 °C, the assays were terminated by three sequential 1 
ml washes with ice cold buffer and then the cells were dissolved in 1 ml of 0.4 M NaOH 
for 24 h. An aliquot (200 ml) was then transferred into a 5 ml glass scintillation vial and 
neutralized with the addition of 5 ml glacial acetic acid followed by 3.5 ml Liquiscint@ 
scintillation fluid (National Diagnostics) to each sample. Incorporation of radioactivity 
was quantified by liquid scintillation counting (LSC, Beckman LS 6500). Values are 
reported as mean ± S.E.M and are corrected for non-specific uptake (e.g., leakage and 
binding) by subtracting the amount of 3H-L-glutamate accumulation at 4°C. 
2.4 Kinetic Analyses 
Michaelis-Menten and Lineweaver–Burk plots and associated kinetic parameters (Km and 
Vmax) for transport inhibitors were estimated using a non-linear curve fitting analysis 
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(KaleidaGraph 3.6.5). Ki determinations from LWB and Eadie-Hofstee replots were 
calculated using linear-regression analysis (KaleidaGraph 3.6.5). 
 
3. RESULTS 
3.1 Inhibition of the SXc--mediated uptake of 3H-L-glutamate 
The inhibitory activity of the compounds was determined by quantifying the ability of the 
analogues to reduce the accumulation of 3H-L-Glu into human SNB-19 glioblastoma 
cells under Cl-dependent (Na-free) conditions.  A number of glioma cell lines, including 
SNB-19, express markedly higher levels of SXc- and reduced levels of the sodium-
dependent excitatory amino acid transporters (EAATs) than do primary astrocytes, 
making them well suited for pharmacological assays of the exchanger (Ye et al., 1999).  
The compounds were initially screened at a single concentration of substrate (100 µM 
3H-L-Glu) and isoxazole (500 µM) to confirm to inhibitory activity.  As reported in Table 
1, all of the analogues almost completely blocked the uptake of the 3H-L-Glu in to cells.  
(The data are reported as % of control uptake, thus the smaller the number the greater the 
level of inhibition.)  The activity for 4-bis-TFM-HMICA (Compound #1, Table 1) has 
been previously reported, although its kinetic mechanism had not been examined in detail 
(see below).  These initial screenings confirmed that the introduction of aryl groups to 
isoxazole scaffold as both mono-substitutions at the 4 or 5 positions or di-substitutions at 
both could produce potent inhibitors of SXc-.  
3.2 Competitive Inhibition of the SXc- by the mono-substituted isoxazoles 
The inhibitory action of 4-bis-TFM-HMICA was characterized in greater detail using a 
standard Michaelis-Menten analysis in which the concentration of both the isoxazole 
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derivative and substrate (3H-L-Glu) were systematically varied. While the inhibitory 
activity of 4-bis-TFM-HMICA has been previously reported, that study did not include a 
characterization of it kinetic mechanism.  A representative series of plots from of these 
assays are depicted in Figure 2, which includes both a V vs. S plot (Panel A) and a 1/V 
vs. 1/S Lineweaver-Burk plot (Panel B).  The pattern of inhibition displayed by 4-bis-
TFM-HMICA is representative of a competitive mechanism and is consistent with the 
inhibitory action of related isoxazoles that have been modified with aryl groups at the C4 
position of the heterocyclic ring (Matti et al., 2013; Patel et al., 2010).  A replot of the 
slopes of the lines from the representative Lineweaver-Burk plot vs. [I] (Figure 2, Panel 
C) was used to determine Ki.  An average of n=3 such analyses yielded a Ki of 61 ± 5 µM 
for 4-bis-TFM-HMICA (Table 1).  A replot of averaged Km,apparent vs. [I] was also linear 
and yielded a similar Ki value (≈ 80 µM), as would be expected for a competitive 
inhibitor (plot not shown) (Segel, 1993).  
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Table 2.1: Percent of Control Uptake of 3H-L-Glu and Ki Values for Sxc- 
Compound 
(500 µM) 
SXc--mediated 
3H-L-Glu 
uptake 
 (% of Control) 
Ki Value 
from LWB 
Slope Replots 
Inhibitory 
Mechanism 
 
1 
(Z)-4-(1-(2-(3,5-
bis(trifluoromethyl)phenyl)hydrazono)eth
yl)-5-methylisoxazole-3-carboxylic acid 
4-bis-TFM-HMICA 
14 ± 4 (n=3) 
 
61 ± 5 µM 
(n=3) 
Competitive 
 
2 
 (Z)-5-benzyl-4-(1-(2-(3,5-
bis(trifluoromethyl)phenyl)hydrazono)eth
yl)isoxazole-3-carboxylic acid 
5-Benzyl-4-bis-TFM-HMICA 
6 ± 1 (n=3) 
 
22 ± 2 µM 
(n=3) 
Noncompetitive 
        
3 
(Z)-4-(1-(2-(3,5-
bis(trifluoromethyl)phenyl)hydrazono)eth
yl)-5-(naphthalen-2-ylmethyl)isoxazole-3-
carboxylic acid 
5-Naphthyl-4-bis-TFM-HMICA 
14 ± 4 (n=3) 
 
13 ± 1 µM 
(n=3) 
Noncompetitive 
        
4 
(Z)-4-(1-(2-(3,5-
bis(trifluoromethyl)phenyl)hydrazono)eth
yl)-5-(4-
(trifluoromethyl)benzyl)isoxazole-3-
carboxylic acid 
5-4-TFM-Benzyl-4-bis-TFM-HMICA 
6 ± 9 (n=5) 
 
3 ± 1 µM 
(n=5) 
Noncompetitive 
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Figure 2.2:  Representative Kinetic Analyses and Ki Determination for  
4-bis-TFM-HMICA 
 
 
 
 
 
SNB-19 cells were assayed for 3H-L-Glutamate uptake under Cl-dependent (Na-free) 
conditions in the presence of a range of inhibitor concentrations.  Data are plotted as 
pmol/min/mg protein and have been corrected for non-specific uptake and leakage.  
Panels A and B, Km (=150 µM) and Vmax (=1100 pmol/min/mg protein) values were 
determined by non-linear curve fitting of the saturation curves and linear regression 
analysis of LWB plots (KaleidaGraph 4.1.3).  Panel C, Ki (70 µM) values were 
determined by linear regression of LWB slope vs. [I] replot.    
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Figure 2.3:  Representative Kinetic Analysis of 5-4-TFM-Benzyl-4-bis-TFM-HMICA  
Displaying Noncompetitive Inhibition 
 
 
 
 
 
Panel A, Michaelis-Menten analysis.  Panel B, LWB replot.  Panel C, LWB slope vs. [I] 
replot.  Panel D, Eadie-Hofstee replot.  Km (≈ 160 µM), Vmax (≈1100 pmol/min/mg 
protein), and Ki (3 µM) values for plots shown were determined using KaleidaGraph 
4.1.3.   
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3.3 Noncompetitive Inhibition of the SXc- by di-substituted isoxazoles 
The di-substituted isoxazole analogues with aryl groups appended at both the #4 and #5 
position were similarly assayed to determine a mechanism of inhibition.  Representative 
plots are shown in Figure 3 for 5-4-TFM-Benzyl-4-bis-TFM-HMICA (Compound #4, 
Table 1), the most potent of the blockers examined.  In contrast to mono-substitutions 
made at either of these positions, all three di-substituted analogues exhibited a pattern of 
inhibition consistent with noncompetitive inhibitors.  Both the V vs. S and Lineweaver-
Burk plots demonstrate that the inhibitors produced a decrease in Vmax with little or no 
change in Km, as would be expected of noncompetitive inhibition.  Again, replots of the 
slopes from the Lineweaver-Burk graphs were linear and used to determine Ki values 
(Table 1). A representative slope replot for 5-4-TFM-Benzyl-4-bis-TFM-HMICA is 
included in Figure 3, Panel C (average Ki = 3 ± 1 µM, n=5).  Competitive and 
noncompetitive inhibitors can also be distinguished by replots from Lineweaver-Burk 
graphs of either Km,apparent vs. [I], linear for competitive mechanisms, or 1/Vmax, apparent vs. 
[I], linear for noncompetitive inhibition (Segel, 1993).  In the instance of 5-4-TFM-
Benzyl-4-bis-TFM-HMICA, the replot of 1/Vmax, apparent vs. [I] was indeed linear and 
yielded a Ki of ≈ 8µM (plots not shown).  If both the slope replot and the 1/Vmax, apparent vs. 
[I] replot yield similar Ki values, as is the case for 5-4-TFM-Benzyl-4-bis-TFM-HMICA, 
the analogue is considered to be acting as a "pure" noncompetitive inhibitor, where the 
binding of the inhibitor does not alter the binding affinity of the substrate (Segel, 1993).  
Interestingly, while the Ki values determined by these two replot methods for 5-4-TFM-
Benzyl-4-bis-TFM-HMICA and 5-Naphthyl-4-bis-TFM-HMICA (Compound #3, Table 
1) were not markedly different, the Ki values for 5-Benzyl-4-bis-TFM-HMICA 
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(Compound #2, Table 1) generated from the 1/Vmax,apparent vs. [I] replots was ≈ 60 µM 
(average n=3), a substantial increase over the ≈ 20µM Ki determined by the slope replot 
method (plots not shown).  This would suggest that in contrast to the other 
noncompetitive inhibitors, the binding of 5-Benzyl-4-bis-TFM-HMICA to SXc- also 
decreased the affinity with which the transporter binds L-Glu. 
As the identification of the di-substituted isoxazoles as noncompetitive inhibitors was 
unexpected, the kinetic data was also analyzed using the Eadie-Hofstee method as a 
second graphical approach.  As depicted in Figure 3 (Panel D) for 5-4-TFM-Benzyl-4-
bis-TFM-HMICA, the plots of V vs. V/[S] for it and 5-Naphthyl-4-bis-TFM-HMICA 
yielded a series of parallel lines, a pattern indicative of noncompetitive inhibition. The 
Eadie-Hofstee plot for 5-Benzyl-4-bis-TFM-HMICA generated non-intersecting lines 
consistent with mixed inhibition (plot not shown).  This pattern of mixed inhibition is 
consistent with the analysis described above in which the binding of the inhibitor also 
reduces the ability of the transporter to bind L-Glu as a substrate.  When the Km/Vmax 
(equivalent to a Lineweaver-Burk slope) and 1/Vmax,apparent values garnered from the 
Eadie-Hofstee graphs were replotted vs. [I], the resulting Ki values were very similar to 
those determined from replots of the Lineweaver-Burk graphs (plots not shown). 
 
4. DISCUSSION 
To the best of our knowledge, the diaryl-substituted isoxazoles described here represents 
the first noncompetitive blockers to be indentified for the SXc-  transport system.  This 
mechanism of action was not anticipated, as these compounds emerged during the course 
of structure-activity-relationship (SAR) studies aimed at the optimization of rationally 
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designed competitive inhibitors.  Thus, the isoxazole scaffold was selected for analogue 
development because of the previously characterized inhibitory activity of a number of 
closely related compounds, including quisqualate, ibotenate, and bromo-homoibotenate 
(Bridges et al., 2012b).  Employing amino-3-carboxy-5-methylisoxazole (ACPA) as a 
starting point, it was found that the inhibitory activity increased as aryl groups were 
systematically introduced at either the 5 position on the isoxazole ring (replacing the 
methyl group on ACPA) or the 4 position of the isoxazole via a hydrazone linkage 
(replacing a-amino acid moiety) (Matti et al., 2013; Patel et al., 2010).  Of these 
derivatives, S-2-naphthyl-ethyl-ACPA emerged as one of the more potent SXc- inhibitors.  
Detailed kinetics analysis similar to those employed in the present study confirmed that it 
competitively inhibited the SXc--mediated uptake of 3H-L-Glu into SNB-19 cells with a 
Ki of about 50 µM (Patel et al., 2010).  Given the structural similarities between the 
analogues, it was assumed at that time that 4-bis-TFM-HMICA, in which the aryl 
substitution was made at the 4 position of the isoxazole ring was also acting as a 
competitive manner.  That this was indeed the case is confirmed in the present report, 
where Michaelis-Menten and Lineweaver-Burk analyses demonstrated it competitively 
inhibited the uptake of 3H-L-Glu into SNB-19 cells with a Ki of about 60 µM.  The 
results also confirm the utility and potency of 4-substituted aryl isoxazole  as inhibitors.   
These SAR data were particularly valuable, as the results suggest that there are lipophilic 
pockets adjacent to the substrate binding site on SXc- and that the presence of these 
domains can be exploited, much in the same manner as has been done with the excitatory 
amino transporters (EAATs) (Bridges R, 2009), to develop more potent and specific 
inhibitors.    
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SAR-based comparisons between the 4- and 5-aryl substituted isoxazole raised intriguing 
questions as to whether the aryl groups were interacting with the same domains on the 
transporter (necessitating a change in the manner in which the isoxazole ring was 
accommodated) or that there are two distinct lipophilic domains present on SXc-.  This 
issue was directly addressed through the synthesis and testing of comparable isoxazoles 
that were modified at both positions.  Although markedly less potent than the mono-
substituted isoxazoles, the ability of these first "hybrid" analogues to also block the SXc--
mediated uptake of 3H-L-Glu into SNB-19 cells supported the conclusion that there were 
at least two distinct lipophilic domains on the transporters, although the mechanism of 
inhibition remained to be elucidated (Patel et al., 2010).  These results prompted the 
optimization of the di-substituted isoxazoles and the preparation of the three analogues 
characterized in the present study.   As initial screening assays suggested that these new 
isoxazoles were among the best inhibitors yet developed for SXc- (Table 1), kinetic 
studies were carried out to determine Ki values.  Surprisingly, the Michaelis-Menten and 
Lineweaver-Burk analyses of the concentration dependence with which the di-substituted 
isoxazoles inhibited the SXc--mediated uptake of 3H-L-Glu into SNB-19 cells revealed a 
noncompetitive mechanism rather than a competitive one.  Similarly, when the uptake 
rates were analyzed using Eadie-Hofstee plots as a second approach, the resulting pattern 
of lines was again indicative of a noncompetitive inhibitor.  The Lineweaver-Burk plots 
were further analyzed by repotting both the slope and 1/Vmax, apparent (1/Vintercept) vs. [I].  If 
a compound is acting as "pure" noncompetitive inhibitor, then these two replots should 
both be linear and yield the same value for Ki (i.e., -X intercept).  This was the case for 5-
4-TFM-Benzyl-4-bis-TFM-HMICA, where its Ki value of about 5 µM places it among 
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the most potent SXc- inhibitors yet identified (Bridges et al., 2012b).  Mechanistically, the 
data suggest this inhibitor can bind to either the empty or substrate-occupied transporter 
to produce a "dead end" complex (i.e., an inactive transporter) and that is does so in a 
manner that does not alter the binding of the substrate (e.g., L-Glu).  Among the three 
isoxazoles examined, only 5-Benzyl-4-bis-TFM-HMICA exhibited a substantial 
difference between the two replots methods, yielding a Ki of about 20 µM from the slope 
replot and 60 µM from the 1/V intercept replot.  While there are different types of mixed 
inhibition involving multiple sites of interaction that could produce such results, the most 
straightforward interpretation suggests that 5-Benzyl-4-bis-TFM-HMICA is 
noncompetitively inhibiting SXc- with a Ki of ≈20 µM, but that when it is bound the 
analogue also reduces the affinity of the transporter for its substrate (Segel, 1993).  Such 
a interpretation is also supported by the fact that the other closely related di-substituted 
isoxazoles are both more potent and act as "pure" noncompetitive inhibitors. 
The switch from a competitive to a noncompetitive mechanism observed with the di-
substituted isoxazoles raises intriguing questions as to the molecular relationships 
between the potential sites of action on SXc-.  Based upon the competitive action of the 
mono-substituted isoxazoles, such as 4-bis-TFM-HMICA, it was hypothesized that the 
isoxazole portion of the molecule was acting as an L-Glu mimic and interacting with 
substrate binding domains, while the trifluoromethyl-substituted benzyl group was 
interacting with an adjacent lipophilic domain.  As a consequence of occupying some 
portion of the substrate site, it would competitively block the binding of L-Glu.  The 5-
monosubstituted isoxazole would be hypothesized to bind in an analogous manner, only 
it would be interacting with a different lipophilic domain, the presence of which is 
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supported by the inhibitory action of the di-substituted "hybrid" isoxazoles.  If this is 
occurring, the present demonstration of the noncompetitive action of the di-substituted 
analogue may reflect the optimal binding of the two aryl groups to their respective 
lipophilic domains in a manner that still inhibits uptake, but also repositions the isoxazole 
ring such that it is no longer directly precludes the binding of L-Glu.  This, in turn, would 
lead to the hypothesis that the substrate binding and lipophilic domains are located in 
close proximity to one another.  The competitive action of the other isoxazoles would 
also be consistent with this model.   Further, lipophilic domains have been identified in a 
number of other transport systems that are in close proximity to the substrate binding 
domains, including the EAATs and the serotonin transport (SERT) (Bridges R, 2009; 
Leary et al., 2011; Zhou et al., 2009).  However, the possibility that the aryl-substituted 
isoxazole are acting at a site well removed from the substrate binding site cannot be 
excluded.  In such an instance, analogue binding would have to produce conformational 
changes that inhibited transport activity in a manner that may or may not have also blocks 
Glu binding, reflecting competitive and noncompetitive mechanisms, respectively.  
Whichever mechanisms are ultimately resolved, the marked increase in the potency of the 
present inhibitors, likely also reflect the presence of the trifluoromethyl groups on the 
aryl substituents. The role of fluorine in enhancing the binding affinity of the ligands 
likely arises from either the proper filling of apolar pockets, multipolar C–F···H–N, C–
F···C=O, and C–F···H–Cα interactions or  polar interaction with electropositive side 
chains (Bissantz et al., 2010; Muller et al., 2007; Zhou et al., 2009; Zurcher et al., 2008) 
}.  It is entirely plausible that with three trifluoromethyl groups present on the most 
potent inhibitor, 5-4-TFM-Benzyl-4-bis-TFM-HMICA, that several types of interactions 
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contribute to the enhanced binding affinity.  Future work within this evolving library of 
compounds will focus on the continued optimization of these aryl group interactions.  
The protein domains with which these ligands interact have been postulated to represent 
either intermediate binding sites guiding substrate permeation (e.g., "vestibule sites") or 
potential allosteric regulatory sites (e.g. "halogen binding pockets") (Singh et al., 2008; 
Zhou et al., 2009).  Ligands occupying these sites may prevent the transporter from 
accessing one or more conformational states within the alternate access mechanism that is 
required for substrate translocation. Ironically, this will likely include exploring different 
linkers between the aryl groups that now, in the face of a noncompetitive mechanism, 
may no longer require the inclusion of a glutamate (or cystine) mimic. 
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Chapter 3.  Supplemental Data 
Using methods described in Chapter 2, extensive pharmacokinetic analysis was 
performed on potential Sxc- inhibitors including analogues of sulfasalazine and ACPA.  A 
subset of these compounds have been documented in previous publications by our lab 
(Newell et al., 2013; Patel et al., 2010).  Supplemental data for these compounds will be 
presented here, along with extensive kinetic data for the remaining compounds within 
this class.  In addition, kinetic data for the endogenous substrate, L-Cys2 is presented in 
Figure 3.1 to demonstrate competitive inhibition.   Competitive inhibition can also be 
seen for the susalimod analogue, RB 553 in Figure 3.2.  Percent of control for each 
compound, as well as KI values for LWB slope replots are presented in Table 3.1 for 
early inhibitors, and in Table 3.2 for novel susalimod and isoxazole analogues.   
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Table 3.1:  Early Inhibitors of Sxc- 
Compound Sxc—mediated 3H-L-Glu Uptake 
(Percent of control) 
Ki  Values  
(µM)* 
 
L-Glutamate 
 
26 ± 3 (n=11) 
 
 
 
 
 
L-Cystine 
 
 
22 ± 3 (n=14) 
 
 
29 ± 10  
 
 
Ibotenate 
 
 
20 ± 1 (6) 
 
 
31 ± 3 
 
 
(RS)-4-Br-Homo-IBO 
 
 
7 ± 1 (7) 
 
 
18 ± 4  
 
 
Quisqualate 
 
 
1 ± 1 (n=9) 
 
 
5 ± 3  
 
 
(S)-4-CPG 
 
 
3 ± 1 (n=3) 
 
 
5 ± 1 
 
 
Sulfasalazine 
 
 
0.5 ± 0.5 (n=3) 
 
 
 
AMPA 
 
 
95 ± 2 (n=6) 
 
 
 
ACPA 
 
 
98 ± 12 (n=3) 
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Table 3.1. Legend 
For percent of control uptake of 3H-L-Glu, SNB-19 cells were assayed for L-[3H]-Glu 
(100 µM) uptake under Cl-dependent (Na-free) conditions in the presence of inhibitor 
(500 µM).  Values are reported as mean ± SEM of control activity (accumulation in the 
absence of inhibitors, i.e. 100%).  For Ki determination, SNB-19 cells were assayed for 
L-[3H]-glutamate uptake in the presence of a range of inhibitor concentrations (10-
500µM). Ki values were determined directly from a re-plot of Lineweaver-Burk slope vs. 
[I] values using linear regression fitting.  Values are reported as mean ± SEM.   
*For Ki values, n ≥ 3. 
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Table 3.2: Susalimod and Isoxasole Compounds  
Compound Sxc—mediated 3H-
L-Glu Uptake 
(Percent of control) 
Ki  from 
LWB slope 
replots 
Inhibitory 
Mechanism 
 
 
1      Susalimod 
 
0.5 ± 0.3 (n=4) 
 
3  ± 0.7 µM 
(n=4) 
 
Competitive 
 
 
2      4-bis-TFM-HMICA 
 
14 ± 4 (n=3) 
 
56 ± 8 µM 
(n=3) 
 
Competitive 
 
 
3     5-benzyl-4-bis-TFM-HMICA 
 
6 ± 1 (n=3) 
 
22 ± 2.5 µM 
(n=3) 
 
Mixed 
       
 
4     5-4-phenylpiperidinyl-4-bis-TFM-HMICA 
 
26 ± 4 (n=3) 
 
59 ± 9 µM 
(n=3) 
 
Mixed 
       
 
5     5-4-biphenyl-4-bis-TFM-HMICA 
 
49 ± 3 (n=3) 
 
97 ± 9 µM 
(n=3) 
 
Mixed  
 
 
6     5-naphthyl-4-bis-TFM-HMICA 
 
13 ± 4 (n=5) 
 
13 ± 1 µM 
(n=3) 
 
Noncompetitive  
 
 
7     5-4-TFM-benzl-4-bis-TFM-HMICA 
 
6 ± 9 (n=5) 
 
3 ± 1 µM 
(n=5) 
 
Noncompetitive 
 
 
8      5-4-methoxy-benzyl-4-bis-TFM-HMICA 
 
4.7 ± 2.7 (n=3) 
 
13 ± 1.6 µM 
(n=3) 
 
Mixed 
 
 
9      5-3-methoxy-benzyl-4-bis-TFM-HMICA 
 
3 ± 1.7 (n=3) 
 
37  ± 12 µM 
(n=5) 
 
Mixed 
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Table 3.2. Legend 
For percent of control uptake of 3H-L-Glu, SNB-19 cells were assayed for L-[3H]-Glu 
(100 µM) uptake under Cl-dependent (Na-free) conditions in the presence of isoxazole-
hydrazone derivatives (500 µM).  Values are reported as mean ± SEM of control activity 
(accumulation in the absence of inhibitors, i.e. 100%).  For Ki determination, SNB-19 
cells were assayed for L-[3H]-glutamate uptake in the presence of a range of inhibitor 
concentrations (10-500µM). Ki values were determined directly from a re-plot of 
Lineweaver-Burk slope vs. [I] values using linear regression fitting.  Values are reported 
as mean ± SEM.   
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Figure 3.1:  L-Cystine – Competitive Inhibition    
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Figure 3.1. Legend 
Representative kinetic analysis of L-Cystine.  Panel A, Michaelis-Menten analysis.  
Panel B, Lineweaver-Burk plot.  Panel C, Eadie-Hofstee plot.  Panel D, LWB Km,apparent 
vs. [I] replot.  Panel E, LWB slope vs. [I] replot.  Panel F, LWB 1/Vmax,apparent vs. [I].  
Km (≈162 µM), Vmax (≈ 985 pmol/min/mg protein), and Ki (29 µM) values for plots 
shown were determined using KaleidaGraph (4.1.3).  Panel G, chemical structure for L-
Cystine.   
This data is consistent with competitive inhibition as seen by the constant Vmax values 
and increasing Km.apparent values.  This is represented by lines intersecting at the Y-axis for 
both the LWB and Eadie-Hofstee plots.  Competitive inhibition is also demonstrated by 
the linear replot of Km.apparent vs. [I] (panel D).   
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Figure 3.2:  Susalimod (1)– Competitive Inhibition         
A           B  
C           D  
E           F  
G  
 
0
200
400
600
800
1000
1200
0 100 200 300 400 500 600
50 uM
30 uM
10 uM
0 uM 
ra
te
 (p
m
ol
es
/m
in
/m
g 
pr
ot
ei
n)
conc. L-glu (uM)
-0.01
0
0.01
0.02
0.03
0.04
0.05
0.06
-0.02 -0.01 0 0.01 0.02 0.03 0.04 0.05
0uM (control)
10uM
30uM
50uM
1/
v 
(1
/p
m
ol
es
/m
in
/m
g 
pr
ot
ei
n)
1/[S]  (1/uM)
0
500
1000
1500
-2 0 2 4 6 8 10
control (0 uM)
10 uM
30 uM
50 uM
ra
te
 (p
m
ol
es
/m
in
/m
g 
pr
ot
ei
n)
rate/[S] ([pmoles/min/mg protein]/uM)
0
100
200
300
400
500
600
700
-10 0 10 20 30 40 50 60
LW
B
 K
m
ap
p
[I] µM
Ki ≈ 12.6 µM
-0.2
0
0.2
0.4
0.6
0.8
1
1.2
-20 0 20 40 60
LW
B
 s
lo
pe
[I] µM
Ki ≈ 3 µM
0
0.0005
0.001
0.0015
0.002
-60 -40 -20 0 20 40 60
LW
B
 1
/V
 in
t
[I] µM
Ki ≈ 51 µM
N
H
N S
O O
OH
COOH
	   47	  
Figure 3.2. Legend 
Representative kinetic analysis of susalimod (1).  Panel A, Michaelis-Menten analysis.  
Panel B, Lineweaver-Burk plot.  Panel C, Eadie-Hofstee plot.  Panel D, LWB Km,apparent 
vs. [I] replot.  Panel E, LWB slope vs. [I] replot.  Panel F, LWB 1/Vmax,apparent vs. [I].   
Km (≈205 µM), Vmax (≈ 1380 pmol/min/mg protein), and Ki (3 µM) values for plots 
shown were determined using KaleidaGraph (4.1.3).  Panel G, chemical structure of 
susalimod. 
This data is consistent with competitive inhibition as seen by the constant Vmax values 
and increasing Km.apparent values.  This is represented by lines intersecting at the Y-axis for 
both the LWB and Eadie-Hofstee plots.  Competitive inhibition is also demonstrated by 
the linear replot of Km.apparent vs. [I] (panel D). 
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Figure 3.3:  4-bis-TFM-HMICA (2) – Competitive Inhibition    
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Figure 3.3. Legend 
Representative kinetic analysis of 4-bis-TFM-HMICA (2).  Panel A, Michaelis-Menten 
analysis.  Panel B, Lineweaver-Burk plot.  Panel C, Eadie-Hofstee plot.  Panel D, LWB 
Km,apparent vs. [I] replot.  Panel E, LWB slope vs. [I] replot.  Panel F, LWB 1/Vmax,apparent 
vs. [I].   Km (≈ 188 µM), Vmax (≈ 1220 pmol/min/mg protein), and Ki (56 µM) values 
for plots shown were determined using KaleidaGraph (4.1.3).   Panel G, chemical 
structure of 4-bis-TFM-HMICA. 
This data is consistent with competitive inhibition as seen by the constant Vmax values 
and increasing Km.apparent values.  This is represented by lines intersecting at the Y-axis for 
both the LWB and Eadie-Hofstee plots.  Competitive inhibition is also demonstrated by 
the linear replot of Km.apparent vs. [I] (panel D). 
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Figure 3.4:  5-benzyl-4-bis-TFM-HMICA (3) – Mixed Inhibition  
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Figure 3.4. Legend 
Representative kinetic analysis of 5-benzyl-4-bis-TFM-HMICA (3).  Panel A, Michaelis-
Menten analysis.  Panel B, Lineweaver-Burk plot.  Panel C, Eadie-Hofstee plot.  Panel 
D, LWB Km,apparent vs. [I] replot.  Panel E, LWB slope vs. [I] replot.  Panel F, LWB 
1/Vmax,apparent vs. [I].   Km (≈ 150 µM), Vmax (≈ 2040 pmol/min/mg protein), and Ki (22 
µM) values for plots shown were determined using KaleidaGraph (4.1.3).  Panel G, 
chemical structure of 5-benzyl-4-bis-TFM-HMICA. 
These data are very difficult to interpret because it contains elements of both competitive 
and noncompetitive inhibition.  For example, with increasing inhibitor concentrations, 
there is an increase in the Km, apparent values and a decrease in the Vmax values.  This can 
also be seen in the LWB plot where the lines are intersecting between the X- and Y-axes.  
Therefore, the mechanism of inhibition for this compound is not fully understood.  In	  
addition,	  since	  the	  Ki	  value	  from	  the	  1/Vmax.apparent	  vs.	  [I]	  is	  considerably	  higher	  than	  that	  of	  
the	  slope	  vs.	  [I]	  plot,	  this	  would	  suggest	  there	  is	  a	  decreased	  affinity	  for	  which	  the	  
transporter	  binds	  L-­‐Glu. 
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Figure 3.5: 5-4-phenylpiperidinyl-4-bis-TFM-HMICA (4) – Mixed Inhibition  
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Figure 3.5. Legend 
Representative kinetic analysis of 5-4-phenylpiperidinyl-4-bis-TFM-HMICA (4).  Panel 
A, Michaelis-Menten analysis.  Panel B, Lineweaver-Burk plot.  Panel C, Eadie-Hofstee 
plot.  Panel D, LWB Km,apparent vs. [I] replot.  Panel E, LWB slope vs. [I] replot.  Panel F, 
LWB 1/Vmax,apparent vs. [I].   Km (≈  160 µM), Vmax (≈  2000 pmol/min/mg protein), and 
Ki (59 µM) values for plots shown were determined using KaleidaGraph (4.1.3).  Panel 
G, chemical structure of 5-4-phenylpiperidinyl-4-bis-TFM-HMICA. 
These data are very difficult to interpret because panel A suggests noncompetitive 
inhibition while panels B and C tend to suggest more competitive inhibition.  With 
increasing inhibitor concentrations there is also an increase in Km, apparent and a decrease in 
Vmax observed for this compound.  Therefore, the mechanism of inhibition for this 
compound is not fully understood. In addition, since the Ki value from the 
1/Vmax.apparent vs. [I] is considerably higher than that of the slope vs. [I] plot, this 
would suggest there is a decreased affinity for which the transporter binds L-Glu. 
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Figure 3.6: 5-4-biphenyl-4-bis-TFM-HMICA (5) – Mixed Inhibition 
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Figure 3.6. Legend 
Representative kinetic analysis of 5-4-biphenyl-4-bis-TFM-HMICA (5).  Panel A, 
Michaelis-Menten analysis.  Panel B, Lineweaver-Burk plot.  Panel C, Eadie-Hofstee 
plot.  Panel D, LWB Km,apparent vs. [I] replot.  Panel E, LWB slope vs. [I] replot.  Panel F, 
LWB 1/Vmax,apparent vs. [I].   Km (≈  180 µM), Vmax (≈  1130 pmol/min/mg protein), and 
Ki (97 µM) values for plots shown were determined using KaleidaGraph (4.1.3).  Panel 
G, chemical structure of 5-4-biphenyl-4-bis-TFM-HMICA. 
These data are very difficult to interpret because panels A and B are suggestive of 
noncompetitive inhibition while panel C has elements of both competitive and 
noncompetitive since the lines are neither intersecting nor parallel.  With increasing 
inhibitor concentrations there is also an increase in Km, apparent and a decrease in Vmax 
observed for this compound, which is suggestive of mixed inhibition.  Therefore, the 
mechanism of inhibition for this compound is not fully understood. In addition, since the 
Ki value from the 1/Vmax.apparent vs. [I] is considerably higher than that of the slope vs. 
[I] plot, this would suggest there is a decreased affinity for which the transporter binds L-
Glu. 
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Figure 3.7:  5-naphthyl-4-bis-TFM-HMICA (6) – Noncompetitive Inhibition 
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Figure 3.7. Legend 
Representative kinetic analysis of 5-naphthyl-4-bis-TFM-HMICA (6).  Panel A, 
Michaelis-Menten analysis.  Panel B, Lineweaver-Burk plot.  Panel C, Eadie-Hofstee 
plot.  Panel D, LWB Km,apparent vs. [I] replot.  Panel E, LWB slope vs. [I] replot.  Panel F, 
LWB 1/Vmax,apparent vs. [I].   Km (≈ 220 µM), Vmax (≈ 1200 pmol/min/mg protein), and 
Ki (13 µM) values for plots shown were determined using KaleidaGraph (4.1.3).  Panel 
G, chemical structure of 5-naphthyl-4-bis-TFM-HMICA. 
This data is consistent with noncompetitive inhibition as seen by the constant Km.apparent 
values and decreasing Vmax values.  This can be seen by lines intersecting at the X-axis 
in the LWP plot, and the parallel lines of the Eadie-Hofstee plot.  Noncompetitive 
inhibition is also demonstrated by the linear 1/Vmax.apparent vs. [I] plot (panel F).  
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Figure 3.8:  5-4-TFM-benzl-4-bis-TFM-HMICA (7) – Noncompetitive Inhibition 
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Figure 3.8. Legend 
Representative kinetic analysis of 5-4-TFM-benzl-4-bis-TFM-HMICA  (7).  Panel A, 
Michaelis-Menten analysis.  Panel B, Lineweaver-Burk plot.  Panel C, Eadie-Hofstee 
plot.  Panel D, LWB Km,apparent vs. [I] replot.  Panel E, LWB slope vs. [I] replot.  Panel F, 
LWB 1/Vmax,apparent vs. [I].   Km (≈ 190 µM), Vmax (≈ 1200 pmol/min/mg protein), and 
Ki (3 µM) values for plots shown were determined using KaleidaGraph (4.1.3).  Panel G, 
chemical structure of 5-4-TFM-benzl-4-bis-TFM-HMICA. 
This data is consistent with noncompetitive inhibition as seen by the constant Km.apparent 
values and decreasing Vmax values.  This can be seen by lines intersecting at the X-axis 
in the LWP plot, and the parallel lines of the Eadie-Hofstee plot.  Noncompetitive 
inhibition is also demonstrated by the linear 1/Vmax.apparent vs. [I] plot (panel F).  
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Figure 3.9:  5-4-methoxy-benzyl-4-bis-TFM-HMICA (8) - Mixed Inhibition  
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Figure 3.8. Legend 
Representative kinetic analysis of 5-4-methoxy-benzyl-4-bis-TFM-HMICA (8).  Panel A, 
Michaelis-Menten analysis.  Panel B, Lineweaver-Burk plot.  Panel C, Eadie-Hofstee 
plot.  Panel D, LWB Km,apparent vs. [I] replot.  Panel E, LWB slope vs. [I] replot.  Panel F, 
LWB 1/Vmax,apparent vs. [I].   Km (≈ 230 µM), Vmax (≈ 1650 pmol/min/mg protein), and 
Ki (13µM) values for plots shown were determined using KaleidaGraph (4.1.3).  Panel 
G, chemical structure of 5-4-methoxy-benzyl-4-bis-TFM-HMICA.  
These data are very difficult to interpret because panels A and C suggest noncompetitive 
inhibition while panel B suggests neither noncompetitive nor competitive inhibition.  
With increasing inhibitor concentrations there is also an increase in Km, apparent and a 
decrease in Vmax observed for this compound.  Therefore, the mechanism of inhibition for 
this compound is not fully understood. In addition, since the Ki value from the 
1/Vmax.apparent vs. [I] is considerably higher than that of the slope vs. [I] plot, this 
would suggest there is a decreased affinity for which the transporter binds L-Glu. 
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Figure 3.10:  5-3-methoxy-benzyl-4-bis-TFM-HMICA (9)– Mixed Inhibition 
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Figure 3.10. Legend 
Representative kinetic analysis of 5-3-methoxy-benzyl-4-bis-TFM-HMICA (9).  Panel A, 
Michaelis-Menten analysis.  Panel B, Lineweaver-Burk plot.  Panel C, Eadie-Hofstee 
plot.  Panel D, LWB Km,apparent vs. [I] replot.  Panel E, LWB slope vs. [I] replot.  Panel F, 
LWB 1/Vmax,apparent vs. [I].   Km (≈ 140 µM), Vmax (≈ 2000 pmol/min/mg protein), and 
Ki (13µM) values for plots shown were determined using KaleidaGraph (4.1.3).  Panel 
G, chemical structure of 5-3-methoxy-benzyl-4-bis-TFM-HMICA. 
These data are very difficult to interpret because panels A and C suggest noncompetitive 
inhibition while panel B suggests neither noncompetitive nor competitive inhibition.  
With increasing inhibitor concentrations there is also an increase in Km, apparent and a 
decrease in Vmax observed for this compound.  Therefore, the mechanism of inhibition for 
this compound is not fully understood. In addition, since the Ki value from the 
1/Vmax.apparent vs. [I] is considerably higher than that of the slope vs. [I] plot, this 
would suggest there is a decreased affinity for which the transporter binds L-Glu. 
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Chapter 4.  Future directions 
The most interesting aspect of my study was the identification of novel inhibitors of Sxc- 
that act through competitive and noncompetitive mechanisms of inhibition.  The 
discovery of noncompetitive inhibitors suggests the possibility for an allosteric binding 
site on the transporter.  Therefore allowing the development of new inhibitors to target a 
site separate from the substrate binding site.  Future development of inhibitors could 
include a new set of compounds with various alterations to the chemical structure.  The 
development of novel inhibitors containing two lipophilic groups but lacking the L-Glu 
or L-Cys2 mimic could be used to determine if inhibitory activity remains and to further 
characterize the lipophilic binding domains.  Other possible alterations could be made to 
the lipophilic domains, the linker group density, or the length of the linker group.   
In addition the development of new inhibitors, additional experiments could be done to 
further characterize the isoxazole hydrazone analogues used in this study.  Fluorometric 
exchange assays could be used to determine substrate activity, to verify the mechanism of 
inhibition seen using the L-Glu uptake experiments, and to help confirm the presence of a 
new binding site.  Detailed kinetic analysis of early inhibitors (such as 4-S-CPG) could 
also be done to help delineate the mechanism of inhibition and help to further develop the 
SAR data at Sxc-.   
In conclusion, the identification of a new binding site is exciting since it provides the 
opportunity to develop very potent inhibitors for Sxc-.  These new inhibitors could lead to 
clinically relevant outcomes in the brain tumor model.   
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